Funding round
Ratio Therapeutics raises $70 million Series C round
Ratio Therapeutics (USA) has raised $70 million in a Series C round, announced on July 31, 2026. The company is Clinical-stage pharmaceutical company developing radiopharmaceuticals for cancer treatment. The round was led by Duquesne Family Office, with participation from Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group.
Ratio Therapeutics closed a $70M Series C to advance its ATLAS trial for targeted radiotherapeutics and expand manufacturing capabilities.
Company
Ratio Therapeutics
Amount
$70 million (~$70M)
Round
Series C
Sector
biotech
Country
USA
Announced
July 31, 2026
Track every raise, every day
This deal appeared in The Daily Raise, July 31, 2026. Get the next edition in your inbox.
Just raised too?
Turn your funding news into guaranteed media coverage while the momentum lasts.